Tiny Tech, Big Impact: Shaping Tomorrow's Medicine with Protein Engineering & Mass Spectrometry

Dive into the future of drug development with "Innovations in Drug Discovery" webinar. This must-attend online event explores two cutting-edge technologies: miniaturized protein engineering and open port mass spectrometry.

Whether you're a biopharma pro, a curious researcher, or just fascinated by drug innovation, this webinar has something for you.

Hear industry leaders discuss cutting-edge pharmaceutical advancements!

Panelists

Leann Teadt (Scientist, Codexis) takes enzyme engineering to the next level, and will show how miniaturization is pushing the boundaries of drug manufacturing. Leann has emerged as a key figure in the field of protein engineering. With five years of dedicated service at Codexis, she serves as a Scientist in the Protein Engineering group. Leann specializes in optimizing high-throughput screens and analytics, demonstrating her proficiency in leveraging cutting-edge technology. Her role extends to technology development, where she actively contributes to innovation and process improvement. She received her Ph.D. in Chemistry from Emory University under the guidance of Dr. Stefan Lutz.

John "Jack" F. Cahill (R&D Associate Scientist, Mass Spectrometry, Oak Ridge National Laboratory) will reveal a revolutionary method for rapid drug characterization using mass spectrometry. Jack is a distinguished R&D Staff Scientist at Oak Ridge National Laboratory, where his impactful contributions have spanned nine years. Armed with a Ph.D. in Analytical Chemistry from UC San Diego, Jack has cemented himself as a leader in the realm of mass spectrometry techniques, specifically focusing on the cutting-edge development and application of the next generation for the chemical characterization of intricate systems. His pioneering research encompasses a diverse array of applications, including high-resolution chemical imaging of tissues, probing chemical dynamics in plant-microbe systems, high-throughput screening, and the revolutionary realm of single-cell analysis by mass spectrometry. 

Holger Armbruster (Global Product Manager, DISPENDIX) will showcase microfluidic technology that's streamlining drug discovery workflows. Holger Armbruster is a product manager with a passion for translating cutting-edge technology into real-world solutions. At DISPENDIX, Holger leads the charge for products, from identifying market needs to guiding them through development and launch. For over 9 years, Holger honed his skills in life science automation at Beckman Coulter, crafting customized solutions for complex workflows. His research background, stemming from a Ph.D. at the German Cancer Research Center (DKFZ) in cancer research, equips Holger with a deep understanding of the scientific landscape and its challenges. Now, Holger leverages this expertise to champion the voice of our customers and translate their needs into innovative DISPENDIX products. 

Attend our webinar to learn about:

• Miniaturized protein engineering: revolutionizing how we make small molecule drugs.
• Open port mass spectrometry: a game-changer for fast and accurate drug analysis.
• The future of drug discovery: how these technologies are paving the way for faster, more efficient treatments.
• Real-world examples: see how these innovations are already making a difference in interdisciplinary scientific investigations.

Register Now

Don't miss this chance to stay ahead of the curve! Register now and gain a deeper understanding of the forces shaping the future of medicine.